Probucol for Symptomatic Intracranial and Extracranial Artery Stenosis

Exclusion Criteria16

• Presumed cardiac source of embolus, such as atrial fibrillation, prosthetic cardiac valve, endocarditis or patent foramen ovale;
• Stroke/TIA due to arterial dissection, angioplasty, or vascular surgery;
• Usage of probucol within 30 days before randomization;
• Known allergy or sensitivity or intolerance to probucol;
• Myocardial disease within the past 30 days, including myocardial infarction, myocarditis;
• With ventricular tachycardia, bradycardia, tip-twist ventricular tachycardia；
• With Q-Tc interval prolongation, or currently using drugs that may cause Q-Tc interval prolongation (male Q-Tc>450ms, female Q-Tc>470ms);
• Cardiac syncope or unexplained syncope;
• Impaired hepatic (ALT or AST > twice the upper limit of normal range) or kidney (creatinine exceeding 1.5 times of the upper limit of normal range or eGFR less than 50 ml/min) function at randomization;
• Anemia (haemoglobin <10g/dL), thrombocytopenia (platelet count <100×109/L) or leucopenia (white blood cell <3×109/L) at randomization;
• Planned surgery or interventional treatment requiring cessation of the study drug during the study;
• Participating in another clinical trial with an investigational drug or device concurrently or during the last 30 days;
• Pregnant or lactating women; Pregnant, currently trying to become pregnant, or of child-bearing potential and not using birth control;
• Severe non-cardiovascular comorbidity with a life expectancy of less than 1 years;
• Serious drug or alcohol abuse in the past 1 year；
• Inability to understand and/or follow research procedures due to mental, cognitive, or emotional disorders, or to be an unsuitable candidate for the study for any other considered by the investigator.